Post-β-receptor impairment in the regulation of myofibrillar Ca2+ sensitivity in tachypacing-induced canine failing heart

S. Satoh, N. Suematsu, Y. Ueda, H. Tsutsui, K. Egashira, A. Takeshita, N. Makino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although one of the salient abnormalities in signal transduction of failing myocardium is downregulation of the β-adrenergic receptor, the extent of presentation of downstream pathways distal to β-receptors is misunderstood. We addressed this question in tachypacing-induced canine failing heart by assessing changes in myofibrillar Ca2+ sensitivity and troponin I phosphorylation. At a basal state, no significant difference in myofibrillar Ca2+ sensitivity was found between normal and failing hearts. Isoproterenol 8-bromo-cylic adenosine monophosphate (cAMP), and 8-bromo-cAMP isobutylmethylxantine all significantly decreased the Ca2+ sensitivity in the normal, but not in the failing, heart. EMD57033 (10 μM), a myofibrillar Ca2+ sensitizer increased the Ca2+ sensitivity to a similar extent in both groups. The troponin I phosphorylation levels were significantly decreased in the failing heart. These results suggest that abnormalities of the β-adrenergic signaling system exist not only at the receptor level but also at downstream steps after cAMP production.

Original languageEnglish
Pages (from-to)88-97
Number of pages10
JournalJournal of Cardiovascular Pharmacology
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 12 2002

Fingerprint

Canidae
Adenosine Monophosphate
Troponin I
Phosphorylation
Isoproterenol
Adrenergic Agents
Adrenergic Receptors
Signal Transduction
Myocardium
Down-Regulation

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Post-β-receptor impairment in the regulation of myofibrillar Ca2+ sensitivity in tachypacing-induced canine failing heart. / Satoh, S.; Suematsu, N.; Ueda, Y.; Tsutsui, H.; Egashira, K.; Takeshita, A.; Makino, N.

In: Journal of Cardiovascular Pharmacology, Vol. 39, No. 1, 12.01.2002, p. 88-97.

Research output: Contribution to journalArticle

@article{febfcfb7020e4b47ac992a2b63dc3540,
title = "Post-β-receptor impairment in the regulation of myofibrillar Ca2+ sensitivity in tachypacing-induced canine failing heart",
abstract = "Although one of the salient abnormalities in signal transduction of failing myocardium is downregulation of the β-adrenergic receptor, the extent of presentation of downstream pathways distal to β-receptors is misunderstood. We addressed this question in tachypacing-induced canine failing heart by assessing changes in myofibrillar Ca2+ sensitivity and troponin I phosphorylation. At a basal state, no significant difference in myofibrillar Ca2+ sensitivity was found between normal and failing hearts. Isoproterenol 8-bromo-cylic adenosine monophosphate (cAMP), and 8-bromo-cAMP isobutylmethylxantine all significantly decreased the Ca2+ sensitivity in the normal, but not in the failing, heart. EMD57033 (10 μM), a myofibrillar Ca2+ sensitizer increased the Ca2+ sensitivity to a similar extent in both groups. The troponin I phosphorylation levels were significantly decreased in the failing heart. These results suggest that abnormalities of the β-adrenergic signaling system exist not only at the receptor level but also at downstream steps after cAMP production.",
author = "S. Satoh and N. Suematsu and Y. Ueda and H. Tsutsui and K. Egashira and A. Takeshita and N. Makino",
year = "2002",
month = "1",
day = "12",
doi = "10.1097/00005344-200201000-00010",
language = "English",
volume = "39",
pages = "88--97",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Post-β-receptor impairment in the regulation of myofibrillar Ca2+ sensitivity in tachypacing-induced canine failing heart

AU - Satoh, S.

AU - Suematsu, N.

AU - Ueda, Y.

AU - Tsutsui, H.

AU - Egashira, K.

AU - Takeshita, A.

AU - Makino, N.

PY - 2002/1/12

Y1 - 2002/1/12

N2 - Although one of the salient abnormalities in signal transduction of failing myocardium is downregulation of the β-adrenergic receptor, the extent of presentation of downstream pathways distal to β-receptors is misunderstood. We addressed this question in tachypacing-induced canine failing heart by assessing changes in myofibrillar Ca2+ sensitivity and troponin I phosphorylation. At a basal state, no significant difference in myofibrillar Ca2+ sensitivity was found between normal and failing hearts. Isoproterenol 8-bromo-cylic adenosine monophosphate (cAMP), and 8-bromo-cAMP isobutylmethylxantine all significantly decreased the Ca2+ sensitivity in the normal, but not in the failing, heart. EMD57033 (10 μM), a myofibrillar Ca2+ sensitizer increased the Ca2+ sensitivity to a similar extent in both groups. The troponin I phosphorylation levels were significantly decreased in the failing heart. These results suggest that abnormalities of the β-adrenergic signaling system exist not only at the receptor level but also at downstream steps after cAMP production.

AB - Although one of the salient abnormalities in signal transduction of failing myocardium is downregulation of the β-adrenergic receptor, the extent of presentation of downstream pathways distal to β-receptors is misunderstood. We addressed this question in tachypacing-induced canine failing heart by assessing changes in myofibrillar Ca2+ sensitivity and troponin I phosphorylation. At a basal state, no significant difference in myofibrillar Ca2+ sensitivity was found between normal and failing hearts. Isoproterenol 8-bromo-cylic adenosine monophosphate (cAMP), and 8-bromo-cAMP isobutylmethylxantine all significantly decreased the Ca2+ sensitivity in the normal, but not in the failing, heart. EMD57033 (10 μM), a myofibrillar Ca2+ sensitizer increased the Ca2+ sensitivity to a similar extent in both groups. The troponin I phosphorylation levels were significantly decreased in the failing heart. These results suggest that abnormalities of the β-adrenergic signaling system exist not only at the receptor level but also at downstream steps after cAMP production.

UR - http://www.scopus.com/inward/record.url?scp=0036137139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036137139&partnerID=8YFLogxK

U2 - 10.1097/00005344-200201000-00010

DO - 10.1097/00005344-200201000-00010

M3 - Article

C2 - 11743231

AN - SCOPUS:0036137139

VL - 39

SP - 88

EP - 97

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -